3,4,5-trihydroxy-N-butyl-benzamide | 110482-92-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3,4,5-trihydroxy-N-butyl-benzamide
• 英文别名: N-butyl-3,4,5-trihydroxybenzamide
• CAS: 110482-92-3
• 化学式: C₁₁H₁₅NO₄
• 分子量: 225.244
• InChiKey: RPXISHBMAMYFNI-UHFFFAOYSA-N

物化性质

• 沸点：
  402.9±45.0 °C(Predicted)
• 密度：
  1.290±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  89.8
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-溴邻苯二酚 、 3,4,5-trihydroxy-N-butyl-benzamide 在 potassium iodate 作用下， 以 水 为溶剂， 生成 2-bromo-N-butyl-3,4,6-trihydroxy-5-oxo-5H-benzo[7]annulene-8-carboxamide
  参考文献：
  名称：

  作为抑制Atg4B的自噬阻滞剂的新型苯并呋喃酮类化合物的合成和评价。

  摘要：

  自噬是一种细胞内降解/再循环途径，可为细胞代谢提供营养和构成要素，并使细胞质清除过时的蛋白质和细胞器。近年来，据报道自噬活性失调是许多不同疾病类型的特征，包括癌症和神经退行性疾病。这为开发自噬调节化合物作为这些疾病的潜在治疗方法提供了有力的依据。已经提出自噬抑制剂作为例如晚期癌症的治疗干预，并且已提出抑制半胱氨酸蛋白酶Atg4B作为阻断自噬的主要策略。我们最近在体内和体外鉴定并证明了-具有针对Atg4B的苯并马酚基础结构的化合物可以显着减慢肿瘤的生长并增强经典化学疗法的作用。在这项研究中，我们报告了在6个不同位置具有其他结构修饰的新苯并三氮杂环丙烷衍生物的合成和抑制作用。为了获得固体抑制谱，对所有化合物进行了三个水平的评估，包括两次基于细胞的测定以确认自噬和细胞内Atg4B抑制作用，以及一次基于SDS-PAGE的实验以评估体外Atg4B亲和力。鉴定了几种具有良好前景的分子。

  DOI：

  10.1016/j.bioorg.2019.03.021
• 作为产物：
  描述：

  没食子酸 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 45.5h， 生成 3,4,5-trihydroxy-N-butyl-benzamide
  参考文献：
  名称：

  发现 TLR1/TLR2 复合物的小分子抑制剂

  摘要：

  作为先天免疫的重要调节剂， Toll 样受体 1 和 2 (TLR1/TLR2) 的蛋白质复合物为治疗各种免疫疾病提供了一个有吸引力的靶点。新型化合物 CU-CPT22 可以与特异性脂蛋白配体竞争结合 TLR1/TLR2（见图），具有高抑制活性和特异性。还观察到来自 TNF-α 和 IL-1β 的下游信号受到抑制。

  DOI：

  10.1002/anie.201204910

文献信息

• [EN] ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 1/2 COMPLEX<br/>[FR] ANTAGONISTES DU COMPLEXE DE RÉCEPTEUR 1/2 DE TYPE TOLL
  申请人：UNIV COLORADO REGENTS

  公开号：WO2014022287A1

  公开（公告）日：2014-02-06

  Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are dislcosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll¬ like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound.

  提供了用于治疗Toll样受体1/2复合物（TLR1/2）相关炎症性疾病的化合物、组合物和方法。基于苯并三酮骨架的小分子，能够影响下游信号传导，以及制备和修改这些分子的方法也已披露。还提供了用于治疗与Toll样受体复合物1/2激活相关的临床状况的方法，包括向受试者施用有效量的苯并三酮化合物。
• [EN] HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS<br/>[FR] BENZOTROPOLONES HALOGÉNÉES EN TANT QU'INHIBITEURS D'ATG4B
  申请人：UNIV ANTWERPEN

  公开号：WO2018096088A1

  公开（公告）日：2018-05-31

  The present invention relates to compounds having a benzotropolone core, and compositions containing said compounds acting as ATG4B inhibitors, thereby inhibiting autophagy. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.

  本发明涉及具有苯并三环酮核的化合物，以及含有该化合物并作为ATG4B抑制剂的组合物，从而抑制自噬。此外，本发明提供了制备所述化合物的方法，以及使用它们的方法，例如作为药物，特别是用于治疗细胞增殖性疾病，如癌症。
• Synthesis and Anticancer Effect of 3,4,5-N-Alkyl-Benzamides on Colon Carcinoma HCT- 116 Cells
  作者：Jilly Octaria Tagore Chan、Ade Arsianti、Maurin Marcelia、Stevano Julio Wijoyo、Fadilah Fadilah、Rista Putrianingsih、Norma Nur Azizah、Hiroki Tanimoto、Kiyomi Kakiuchi

  DOI：10.13005/ojc/340323

  日期：2018.6.28

  The natural phenolic gallic acid has demonstrated a significant inhibition of cell proliferation in a series of cancer cell lines, as well as induced apoptosis in  HCT-116 colon cancer cells. This research aims to synthesize six compounds of 3,4,5-trihydroxy-N-alkyl-benzamide derivatives of  gallic acid, and investigate its anticancer effect on colon carcinoma HCT-116 cells.Six compounds of 3,4,5-trihydroxy-N-alkyl-benzamide, namely 3,4,5-trihydroxy-N-methyl-benzamide (2); 3,4,5-trihydroxy-N-ethyl-benzamide (3); 3,4,5-trihydroxy-N-butyl-benzamide (4); 3,4,5-trihydroxy-N-sec-butyl-benzamide (5); 3,4,5-trihydroxy-N-tert-butyl-benzamide (6) and 3,4,5-trihydroxy-N-hexyl-benzamide (7), have been successfully synthesized by amidation of carboxyl group of gallic acid with six corresponding alkylamines, respectively. Furthermore, anticancer effect of these six synthesized derivatives on colon HCT-116 cells were examined by MTT assay. Data were analyzed by linear regression method to generate IC50 value. The results will be compared with gallic acid as an original compound and doxorubicine as a positive control.Amidation of gallic acid with six corresponding alkylamines gave desired -N-methyl-, -N-ethyl-, -N-butyl-, -N-sec-butyl-, -N-ters-butyl-, and –N-hexyl benzamide with yield ranging from 18% to 84%. Compared to gallic acid (IC50: 0.05 µM) and doxorubicine (IC50: 0.001 µM), all these six synthesized derivatives showed a lower anticancer effect on colon HCT-116 cells. The strongest anticancer and inhibitory effect on HCT-116 cells has shown by 3,4,5-trihydroxy-N-hexyl benzamide (7) with IC50 value of 0.07 µM. Our results suggested that 3,4,5-trihydroxy-N-hexyl benzamide (7) is a potential to be developed as a promising anti-colon cancer agent.

  16细胞。
• ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 1/2 COMPLEX
  申请人：THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate

  公开号：US20150251987A1

  公开（公告）日：2015-09-10

  Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are disclosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll-like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound.

  提供了用于治疗Toll样受体1/2复合物（TLRI/2）相关炎症性疾病的化合物、组合物和方法。公开了基于苯并三环酮支架的小分子，能够影响下游信号传导，以及制备和修改这些分子的方法。还提供了用于治疗与Toll样受体复合物1/2激活相关的临床状况的方法，包括向受试者施用有效量的苯并三环酮化合物。
• Halogenated benzotropolones as ATG4B inhibitors
  申请人：Universiteit Antwerpen

  公开号：US10738002B2

  公开（公告）日：2020-08-11

  The present invention relates to compounds having a benzotropolone core, and compositions containing said compounds acting as ATG4B inhibitors, thereby inhibiting autophagy. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer. Halogenated benzotropolones described here are of formula

  本发明涉及具有苯并酞酮核心的化合物，以及含有上述化合物的组合物，这些化合物可作为 ATG4B 抑制剂，从而抑制自噬。此外，本发明还提供了制备所公开化合物的工艺，以及使用这些化合物的方法，例如将其用作药物，特别是用于治疗细胞增殖性疾病，如癌症。本发明所述卤代苯并酞酮的化学式为